• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - RCKT

By: Pomerantz LLP via GlobeNewswire
July 18, 2025 at 12:00 PM EDT

NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ: RCKT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Rocket and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until August 11, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Rocket securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.         

[Click here for information about joining the class action]

On May 27, 2025, Rocket issued a press release “announc[ing] an update related to RP-A501, its investigational gene therapy for Danon disease.”  The press release disclosed that “[a] patient participating in the Phase 2 pivotal trial of RP-A501 experienced an unexpected Serious Adverse Event (SAE)” that “involved clinical complications related to a capillary leak syndrome.”  The press release said that “[u]pon learning of the initial event, Rocket voluntarily paused further dosing in the study” and that “[o]n May 23, 2025, the FDA placed a clinical hold on the trial to allow for further evaluation.”  Finally, the press release noted that the patient in question “has since passed away after an acute systemic infection.” 

On this news, Rocket’s stock price fell $3.94 per share, or 62.84%, to close at $2.33 per share on May 27, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
dpeyton@pomlaw.com
646-581-9980 ext. 7980


More News

View More
Rocket Lab: A Parabolic Run Meets a Healthy Pullback
July 23, 2025
Via MarketBeat
Tickers RKLB
Falling Fast, Rising Soon? 3 Stocks With Upside Ahead
July 23, 2025
Via MarketBeat
Topics Earnings
Tickers ALLT ARDT GPI
The Top 120 Lesser-Known Affordable Luxury Vacation Spots in the U.S.
July 23, 2025
Via MarketBeat
Healthcare Stocks Hit Valuation Bottom, 3 Names to Rebound
July 23, 2025
Via MarketBeat
Topics Artificial Intelligence
Tickers LLY PFE UNH
Is Former Dividend Aristocrat AT&T a Buy After Q2 Earnings?
July 23, 2025
Via MarketBeat
Topics Earnings
Tickers T TMUS VZ
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap